临床决策支持工具预测炎症性肠病患者维得利珠单抗治疗结局的应用:KASID多中心研究
该研究在韩国10家三级转诊中心回顾性纳入143例克罗恩病和219例溃疡性结肠炎患者,验证临床决策支持工具(CDSTs)预测维得利珠单抗真实疗效的准确性。结果显示CDSTs对溃疡性结肠炎的临床和生化结局预测具有可接受的准确性,但在克罗恩病中的效用有限。
要点
- 溃疡性结肠炎中,CDSTs预测第14、26、54周临床缓解和应答均呈递增趋势(ptrend<0.001)。
- 克罗恩病中,仅第14周无激素临床应答呈递增趋势(ptrend=0.004),药物优化或转换需求呈递减趋势(ptrend=0.016)。
- 以26分为截断值,CDSTs对溃疡性结肠炎第14周无激素临床应答、第26周BioRES[CRP]和BioRES[FC]、第54周BioRES[CRP]的AUC均>0.600,但对克罗恩病准确性差。
核心结论
- CDSTs预测维得利珠单抗在溃疡性结肠炎中的临床和生化结局具有可接受的准确性,但在克罗恩病中的效用有限。
研究设计与样本
- 回顾性纳入2017年1月至2021年11月韩国10家三级转诊中心接受维得利珠单抗治疗的143例克罗恩病和219例溃疡性结肠炎患者。
主要发现
- 克罗恩病中,从低到高概率组,第14周无激素临床应答呈递增趋势(ptrend=0.004),药物优化或转换需求呈递减趋势(ptrend=0.016)。
- 溃疡性结肠炎中,除第54周无激素临床缓解外,第14、26、54周所有临床应答均呈递增趋势(ptrend<0.001);第26和54周BioRES[CRP]及第14周EH也呈递增趋势(ptrend<0.05);药物优化或转换需求随应答概率增加而减少(ptrend=0.013)。
- 以26分为截断值,CDSTs有效识别溃疡性结肠炎第14周无激素临床应答、第26周BioRES[CRP]、BioRES[FC]和第54周BioRES[CRP],AUC均>0.600;克罗恩病中CDSTs准确性差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: We aimed to validate clinical decision support tools (CDSTs) to predict real-life effectiveness of vedolizumab (VDZ) in patients with inflammatory bowel disease. METHODS: We retrospectively enrolled patients with Crohn's disease (CD) or ulcerative colitis (UC) treated with VDZ at 10 tertiary referral centres in Korea between January 2017 and November 2021. We assessed clinical remission (CREM) and response (CRES), corticosteroid-free clinical remission (CSF-CREM) and response (CSF-CRES), biochemical response based on C-reactive protein (BioRES[CRP]) and faecal calprotectin (BioRES[FC]), endoscopic healing (EH), and the need to optimise or switch drugs based on CDST-defined response groups. Additionally, the area under the receiver operating characteristics curve (AUC) for the CDSTs was calculated. RESULTS: We included 143 patients with CD and 219 with UC. We observed incremental trends on CSF-CRES at week 14 (W14) (ptrend = 0.004) and decreasing trends for the need to optimise or switch drugs (ptrend = 0.016) in CD from the low to high probability groups. Except for CSF-CREM at W54, we noticed incremental trends for all clinical responses at W14, W26 and W54 (ptrend <0.001) in UC. W26 and W54 BioRES[CRP] and W14 EH also showed increasing trends (ptrend <0.05) in UC. With increasing probabilities of response, drug optimisation or switching was less frequently required in UC (ptrend = 0.013). With 26 points cut-off, CDSTs effectively identified W14 CSF-CRES, W26 BioRES[CRP], BioRES[FC] and W54 BioRES[CRP] in UC, all with AUCs >0.600, whereas CDSTs showed poor accuracy in CD. CONCLUSIONS: CDSTs for VDZ had acceptable accuracy in predicting effectiveness outcomes including clinical and biochemical outcomes in UC. However, their utility in CD was limited.
引用
- Kim K, Park JJ, Yoon H, et al. Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study. Aliment Pharmacol Ther. 2024. PMID: 38616380. doi:10.1111/apt.17989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。